A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related
CONCLUSION: MPN-BP and AML-MR harbor similar somatic mutations and clinical outcomes, suggesting a unified clinical disease entity.PMID:38665121 | DOI:10.1111/ijlh.14280 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 26, 2024 Category: Hematology Authors: Dong Chen Julia Geyer Adam Bagg Robert Hasserjian Olga K Weinberg Source Type: research
RNF138 inhibits transcription factor C/EBP α protein turnover leading to differentiation arrest in AML
Biochem J. 2024 Apr 26:BCJ20240027. doi: 10.1042/BCJ20240027. Online ahead of print.ABSTRACTE3 ubiquitin ligase, ring finger protein 138 (RNF138) is involved in several biological processes; however, its role in myeloid differentiation or tumorigenesis remains unclear. RNAseq data from TNMplot showed that RNF138 mRNA levels are highly elevated in Acute Myeloid Leukemia (AML) bone marrow samples as compared to bone marrow of normal volunteers. Here, we show that RNF138 serves as an E3 ligase for the tumor suppressor CCAAT/enhancer binding protein (C/EBPα) and promotes its degradation leading to myeloid differentiation arre...
Source: The Biochemical Journal - April 26, 2024 Category: Biochemistry Authors: Anil Kumar Singh Vishal Upadhyay Arppita Sethi Sangita Chaowdhury Shivkant Mishra Shailednra Prasad Verma Madan Lal Brahma Bhatt Arun Kumar Trivedi Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184.ABSTRACTTargeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML). The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. AML cells represented all major morphologic and molecular subtypes, includi...
Source: Current Issues in Molecular Biology - April 26, 2024 Category: Molecular Biology Authors: Katja Seipel Harpreet Mandhair Ulrike Bacher Thomas Pabst Source Type: research
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.ABSTRACTMyelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutati...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daniel Karel Claire Valburg Navitha Woddor Victor E Nava Anita Aggarwal Source Type: research
The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia
Oncogene, Published online: 26 April 2024; doi:10.1038/s41388-024-02998-2The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia (Source: Oncogene)
Source: Oncogene - April 26, 2024 Category: Cancer & Oncology Authors: Guangming Wang Wenjun Zhang Jie Ren Yu Zeng Xiuyong Dang Xiaoxue Tian Wenlei Yu Zheng Li Yuting Ma Pingping Yang Jinyuan Lu Junke Zheng Bing Lu Jun Xu Aibin Liang Source Type: research
